DDInter734 DDInter822
Fidaxomicin is a novel macrolide antibiotic used in the treatment of diarrhea caused by _Clostridioides_ (formerly _Clostridium_) _difficile_ in adult and pediatric patients over the age of 6 months. Fidaxomicin is a naturally-occurring 18-member macrocycle derived from fermentation. Because fidaxomicin contains an 18-membered lactone ring in its structure, it is referred to as a macrocyclic lactone antibiotic drug. The antibacterial activity of fidaxomicin is distinct from macrolides and rifamycins, as the bactericidal activity is time-dependent, and not concentration-dependent. Fidaxomicin was the first macrocyclic lactone antibiotic with activity against _C. difficile_, and it displays a narrow spectrum of activity against gram-positive anaerobes. It mediates its potent bactericidal action on the bacteria by inhibiting the bacterial RNA synthase
Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionality. The great lipophilicity of this group of compounds brought interest to further modification. This analysis concluded that the presence of p-cyano ureas presented good physicochemical and pharmacokinetic properties from which glasdegib was developed. Glasdegib was developed by Pfizer Inc and approved on November 21, 2018 by the FDA for the treatment of Acute Myeloid Leukemia (AML). Glasdegib targets cancerous cells by inhibiting the sonic hedgehog receptor smoothened (SMO), a transmembrane protein involved in the Hedgehog (Hh) signaling cascade. Aberrant of Hh signaling is one of the main pathophysiologies of AML, with observed overexpression or constitutive activation of SMO.[A258498,A258503] Although the efficacy of glasdegib monotherapy is limited, the landmark Phase 2 Bright AML 1003 trial showed a superior overall survival and complete response when glasdegib is combined with low dose cytarabine. Currently, the current gold standard of AML in older patients is still venetoclax with hypomethylation agents, new clinical combinations of glasdegib are being tested in hope of replacing venetoclax due to glasdegib's more favorable side effects profile.
Fidaxomicin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Amprenavir
Amprenavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glasdegib
Fidaxomicin {u} (Compound) is included by {v} (Pharmacologic Class) Macrolides
Macrolides {u} (Pharmacologic Class) includes {v} (Compound) Clarithromycin
Clarithromycin {u} may lead to a major life threatening interaction when taken with {v} Glasdegib
Fidaxomicin {u} (Compound) causes {v} (Side Effect) Flatulence
Flatulence {u} (Side Effect) is caused by {v} (Compound) Amoxapine
Amoxapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glasdegib
Fidaxomicin {u} (Compound) is included by {v} (Pharmacologic Class) Macrolides
Macrolides {u} (Pharmacologic Class) includes {v} (Compound) Azithromycin
Azithromycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glasdegib
Fidaxomicin {u} (Compound) causes {v} (Side Effect) Flatulence
Flatulence {u} (Side Effect) is caused by {v} (Compound) Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Glasdegib
Fidaxomicin {u} (Compound) causes {v} (Side Effect) Gastrointestinal disorder
Gastrointestinal disorder {u} (Side Effect) is caused by {v} (Compound) Nafcillin
Nafcillin {u} may lead to a major life threatening interaction when taken with {v} Glasdegib
Fidaxomicin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Boceprevir
Boceprevir {u} may lead to a major life threatening interaction when taken with {v} Glasdegib
Fidaxomicin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Amprenavir (Compound) and Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Fidaxomicin (Compound) is included by Macrolides (Pharmacologic Class) and Macrolides (Pharmacologic Class) includes Clarithromycin (Compound) and Clarithromycin may lead to a major life threatening interaction when taken with Glasdegib
Fidaxomicin (Compound) causes Flatulence (Side Effect) and Flatulence (Side Effect) is caused by Amoxapine (Compound) and Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Fidaxomicin (Compound) is included by Macrolides (Pharmacologic Class) and Macrolides (Pharmacologic Class) includes Azithromycin (Compound) and Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Fidaxomicin (Compound) causes Flatulence (Side Effect) and Flatulence (Side Effect) is caused by Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Fidaxomicin (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Nafcillin (Compound) and Nafcillin may lead to a major life threatening interaction when taken with Glasdegib
Fidaxomicin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Boceprevir (Compound) and Boceprevir may lead to a major life threatening interaction when taken with Glasdegib